Inactive Instrument

Highlights Silence Therapeutics plc London S.E.

Equities

SLN

GB00B9GTXM62

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	Apr. 19	MT
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	Apr. 16	MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	Apr. 15	MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	Apr. 12	MT
Silence Therapeutics plc Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)	Apr. 08	CI
Silence Therapeutics' 2023 Loss Narrows, Revenue Rises	Mar. 13	MT
Silence Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
Silence Therapeutics plc Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(A)	Mar. 13	CI
Gubra Concludes the Research Agreement with Silence Therapeutics plc	Jan. 26	CI
Silence Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Silence Therapeutics plc Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease	Nov. 01	CI
Silence Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-16	CI
Earnings Flash (SLN) SILENCE THERAPEUTICS Reports Q1 Revenue GBP11.4M	23-05-16	MT
Silence Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-16	CI
Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran in Subjects with Elevated Lipoprotein(A) At High Risk of Atherosclerotic Cardiovascular Disease Events	23-05-01	CI
Silence Therapeutics plc Announces Publication in Blood Demonstrating Role for Iron Regulation in Polycythemia Vera	23-04-04	CI
Silence Therapeutics to Buy Back Two Assets From Mallinckrodt; Shares Rise Pre-Bell	23-03-28	MT
Silence Therapeutics' 2022 Loss Narrows, Revenue Increases	23-03-15	MT
Silence Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Silence Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Silence Therapeutics plc London S.E.

Equities

SLN

GB00B9GTXM62

Highlights

Filters